The effects of FH deficiency suggest several drug development avenues, including VEGF inhibitors, DNMT (DNA methyltransferases) inhibitors, PARP inhibitors, and LDHA (lactate dehydrogenase) inhibitors [5,6,7]. The gene discussed is FH; the disease is hyperinsulinemic hypoglycemia, familial, 4.